MYO10

Summary

MYO10 (myosin X, HGNC:7593) is a protein-coding gene on chromosome 5p15.1, encoding Unconventional myosin-X (Q9HD67). Myosins are actin-based motor molecules with ATPase activity.

This gene encodes a member of the myosin superfamily. The protein represents an unconventional myosin; it should not be confused with the conventional non-muscle myosin-10 (MYH10). Unconventional myosins contain the basic domains of conventional myosins and are further distinguished from class members by their tail domains. This gene functions as an actin-based molecular motor and plays a role in integration of F-actin and microtubule cytoskeletons during meiosis.

Source: NCBI Gene 4651 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 430 total — 1 pathogenic, 1 likely-pathogenic
• MANE Select transcript: NM_012334

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7593
Approved symbol	MYO10
Name	myosin X
Location	5p15.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0799, MyoX
Ensembl gene	ENSG00000145555
Ensembl biotype	protein_coding
OMIM	601481
Entrez	4651

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 7 protein_coding, 3 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000274203, ENST00000502436, ENST00000505695, ENST00000506343, ENST00000507288, ENST00000508318, ENST00000510401, ENST00000511972, ENST00000512061, ENST00000513610, ENST00000513882, ENST00000515803

RefSeq mRNA: 1 — MANE Select: NM_012334 NM_012334

CCDS: CCDS54834

Canonical transcript exons

ENST00000513610 — 41 exons

Exon	Start	End
ENSE00000970959	16681309	16681503
ENSE00000970960	16679947	16680104
ENSE00000970961	16676031	16676154
ENSE00000970962	16674853	16675150
ENSE00000970964	16672689	16672825
ENSE00000970965	16671422	16671542
ENSE00001014343	16681871	16682013
ENSE00001122943	16685738	16685831
ENSE00001122951	16694371	16694614
ENSE00001122958	16699450	16699573
ENSE00001122968	16700963	16701838
ENSE00001208355	16689824	16689919
ENSE00001279984	16668277	16668468
ENSE00001294318	16683880	16683935
ENSE00001296097	16670526	16670978
ENSE00001310382	16702925	16703158
ENSE00001316367	16673682	16673889
ENSE00001402124	16763481	16763547
ENSE00001402858	16780524	16780608
ENSE00001407326	16763655	16763755
ENSE00001409657	16781705	16781829
ENSE00001411614	16702543	16702588
ENSE00001412870	16764250	16764396
ENSE00001414832	16783335	16783469
ENSE00001418097	16761464	16761546
ENSE00001420775	16766080	16766198
ENSE00001422620	16794646	16794833
ENSE00001426072	16762045	16762113
ENSE00001426702	16769074	16769203
ENSE00001427527	16818009	16818167
ENSE00001429727	16762545	16762637
ENSE00001430380	16779545	16779648
ENSE00001433458	16877609	16877707
ENSE00001663224	16780728	16780741
ENSE00002074062	16661907	16666793
ENSE00002079060	16935788	16936288
ENSE00003538968	16710908	16711022
ENSE00003545746	16758118	16758226
ENSE00003581034	16754828	16754908
ENSE00003658634	16704579	16704685
ENSE00003681615	16711121	16711245

Expression profiles

Bgee: expression breadth ubiquitous, 290 present calls, max score 98.09.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 37.2935 / max 732.0343, expressed in 1639 samples.

FANTOM5 promoters (21 alternative TSS)

Promoter ID	TPM avg	Samples expressed
61047	28.3481	1617
61024	1.8385	289
61030	1.3904	237
61025	0.9981	279
61023	0.9269	255
61034	0.7676	201
61046	0.5344	282
61029	0.3790	151
61032	0.3633	172
61031	0.3161	141

Top tissues by expression

297 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	98.09	gold quality
medial globus pallidus	UBERON:0002477	98.08	gold quality
globus pallidus	UBERON:0001875	98.03	gold quality
lateral globus pallidus	UBERON:0002476	97.96	gold quality
ventricular zone	UBERON:0003053	97.72	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	97.69	gold quality
inferior olivary complex	UBERON:0002127	97.62	gold quality
CA1 field of hippocampus	UBERON:0003881	97.61	gold quality
choroid plexus epithelium	UBERON:0003911	96.56	gold quality
middle frontal gyrus	UBERON:0002702	96.19	gold quality
tendon of biceps brachii	UBERON:0008188	96.15	gold quality
medulla oblongata	UBERON:0001896	95.84	gold quality
cartilage tissue	UBERON:0002418	95.59	gold quality
subthalamic nucleus	UBERON:0001906	95.54	gold quality
renal medulla	UBERON:0000362	95.49	gold quality
periodontal ligament	UBERON:0008266	95.48	gold quality
mucosa of sigmoid colon	UBERON:0004993	95.21	gold quality
tibia	UBERON:0000979	95.20	gold quality
corpus callosum	UBERON:0002336	95.11	gold quality
superior vestibular nucleus	UBERON:0007227	95.11	gold quality
pylorus	UBERON:0001166	95.09	gold quality
inferior vagus X ganglion	UBERON:0005363	94.80	gold quality
ventral tegmental area	UBERON:0002691	94.74	gold quality
hair follicle	UBERON:0002073	94.65	gold quality
substantia nigra pars reticulata	UBERON:0001966	94.56	gold quality
colonic mucosa	UBERON:0000317	94.53	gold quality
visceral pleura	UBERON:0002401	94.50	gold quality
entorhinal cortex	UBERON:0002728	94.43	gold quality
Brodmann (1909) area 46	UBERON:0006483	94.31	gold quality
parietal lobe	UBERON:0001872	94.25	gold quality

Single-cell (SCXA)

Detected in 9 experiment(s), a significant marker in 8.

Experiment	Marker?	Max mean expression
E-HCAD-23	yes	1072.39
E-MTAB-3929	yes	166.49
E-HCAD-5	yes	36.08
E-CURD-119	yes	24.68
E-MTAB-7316	yes	21.85
E-GEOD-81608	yes	17.92
E-GEOD-93593	yes	14.97
E-CURD-89	no	26.42
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

198 targeting MYO10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-3912-5P	99.95	66.11	925
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426

Literature-anchored findings (GeneRIF, showing 31)

• M10 is a specific motor carrying Mena/VASP from the root to the tip of the filopodia where extension of actin filament takes place (PMID:15158464)
• Results report that, in addition to full-length myosin 10 (Myo10), brain expresses a shorter form of Myo10 that lacks a myosin head domain. (PMID:16371656)
• Data demonstrate that Myo10 is a molecular motor that functions in filopodia formation. (PMID:16894163)
• Our data suggest that CLP functions to increase translation of Myo10 possibly by acting as a chaperone for the emerging Myo10 heavy chain protein. (PMID:18295593)
• myosin X recognizes the local structural arrangement of filaments in long bundles, providing a mechanism for sorting cargo to distant target sites. (PMID:18599451)
• increased CLP expression and CLP-mediated Myo10 function are important for skin differentiation and wound reepithelialization (PMID:18818677)
• Results suggest that VE-cadherin trafficking along filopodia using myosin-X motor protein is a prerequisite for cell-cell junction formation. (PMID:20123970)
• Results indicate that PtdIns(3,4,5)P binding to the Myo10-PH2 domain is involved in Myo10 trafficking and regulation of filopodia dynamics. (PMID:20930142)
• The structure of the MyoX MyTH4-FERM tandem in complex with the cytoplasmic tail P3 domain of the netrin receptor DCC, is reported. (PMID:21321230)
• Molecular basis by which myosin-X facilitates alternative dual binding to cargos and microtubules. (PMID:21642953)
• Authors conclude thatMyo10 generates the force to enhance bacterial-induced cell membrane protrusions by binding its head region to actin filaments and its PH tail domain to the peripheral membrane. (PMID:23083060)
• Study demonstrates a novel biological function for Hdl-Myo10 and an important new role for both Myo10 isoforms in the development of dendritic spines and synapses. (PMID:23943878)
• Phosphorylation of ADD1 at Ser12 and Ser355 by cyclin-dependent kinase 1 enables ADD1 to bind to myosin-X (Myo10). (PMID:24379415)
• Myo10 upregulation in mutant p53-driven cancers is necessary for invasion and that plasma-membrane protrusions. (PMID:24487586)
• Elevated MYO10 expression and involvement in invadopodia formation increases the aggressiveness of breast cancer . (PMID:24921915)
• PCTK1 regulates spindle orientation through phosphorylation of Ser83 on KAP0, a regulatory subunit of protein kinase A. (PMID:25605337)
• Results suggest that NF-kappaB-regulated miR-124 targets MYO10, inhibits cell invasion and metastasis, and is down-regulated in node-positive NSCLC. (PMID:25749519)
• New research implicates Myo10 in a number of disease states including cancer metastasis and pathogen infection. (PMID:25819274)
• Myo10 plays a key role in integrating the actin and microtubule cytoskeletons to position centrosomes and mitotic spindles. (PMID:26235048)
• MYO10 (myosin X), a direct miR340 target gene, mediated the migration and invasion of breast cancer cells (PMID:26573744)
• In two cohorts with available data, we identified one intronic SNP (rs13361131) in myosin X gene (MYO10) associated with C17:0 level (P = 1.37x10-8), and two intronic SNP (rs12874278 and rs17363566) in deleted in lymphocytic leukemia 1 (DLEU1) region associated with C19:0 level (P = 7.07x10-9) (PMID:29738550)
• miR-129 inhibited neuroblastoma growth and potentiated chemosensitivity by targeting MYO10 (PMID:29864913)
• MYO10 represents a new clinical biomarker for this aggressive disease and due to its role in cellular motility and invasion (PMID:29934580)
• We demonstrated that circMYO10 is upregulated in OS tissues and cell lines. CircMYO10 activates Wnt/beta-catenin signaling by regulating miR-370-3p/RUVBL1 axis to promote H4K16Ac at the promoter region of beta-catenin/LEF1 target genes. (PMID:31665067)
• LncRNA SNHG7 enhances chemoresistance in neuroblastoma through cisplatin-induced autophagy by regulating miR-329-3p/MYO10 axis. (PMID:32329857)
• Elevated MYO10 Predicts Poor Prognosis and its Deletion Hampers Proliferation and Migration Potentials of Cells Through Rewiring PI3K/Akt Signaling in Cervical Cancer. (PMID:32618228)
• Myosin-X and talin modulate integrin activity at filopodia tips. (PMID:34525374)
• MYO10 promotes transzonal projection-dependent germ line-somatic contact during mammalian folliculogenesisdagger. (PMID:35470858)
• MYO10 contributes to the malignant phenotypes of colorectal cancer via RACK1 by activating integrin/Src/FAK signaling. (PMID:35912545)
• MYO10-filopodia support basement membranes at pre-invasive tumor boundaries. (PMID:36283390)
• MYO10 regulates genome stability and cancer inflammation through mediating mitosis. (PMID:37200188)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	myo10	ENSDARG00000017004
mus_musculus	Myo10	ENSMUSG00000022272
rattus_norvegicus	Myo10	ENSRNOG00000010161

Paralogs (44): MYH13 (ENSG00000006788), MYO16 (ENSG00000041515), MYO9A (ENSG00000066933), MYO3B (ENSG00000071909), MYH7B (ENSG00000078814), MYO15A (ENSG00000091536), MYH7 (ENSG00000092054), MYO3A (ENSG00000095777), MYO9B (ENSG00000099331), MYH9 (ENSG00000100345), MYH14 (ENSG00000105357), MYH1 (ENSG00000109061), MYH3 (ENSG00000109063), MYH2 (ENSG00000125414), MYO1B (ENSG00000128641), MYO5C (ENSG00000128833), CGNL1 (ENSG00000128849), MYH8 (ENSG00000133020), MYH10 (ENSG00000133026), MYH11 (ENSG00000133392), MYO18B (ENSG00000133454), CCDC102A (ENSG00000135736), MYO1G (ENSG00000136286), MYO7A (ENSG00000137474), MYO1F (ENSG00000142347), CGN (ENSG00000143375), TMF1 (ENSG00000144747), MYH15 (ENSG00000144821), CCDC102B (ENSG00000150636), MYO1E (ENSG00000157483), CCDC158 (ENSG00000163749), MYO1A (ENSG00000166866), MYO5B (ENSG00000167306), MYO7B (ENSG00000169994), MYO1H (ENSG00000174527), MYO1D (ENSG00000176658), MYO18A (ENSG00000196535), MYO6 (ENSG00000196586), MYO5A (ENSG00000197535), MYH6 (ENSG00000197616)

Protein

Protein identifiers

Unconventional myosin-X — Q9HD67 (reviewed: Q9HD67)

Alternative names: Unconventional myosin-10

All UniProt accessions (5): A0A0A0MQX1, D6RGD1, E9PCN3, E9PEW5, Q9HD67

UniProt curated annotations — full annotation on UniProt →

Function. Myosins are actin-based motor molecules with ATPase activity. Unconventional myosins serve in intracellular movements. MYO10 binds to actin filaments and actin bundles and functions as a plus end-directed motor. Moves with higher velocity and takes larger steps on actin bundles than on single actin filaments. The tail domain binds to membranous compartments containing phosphatidylinositol 3,4,5-trisphosphate or integrins, and mediates cargo transport along actin filaments. Regulates cell shape, cell spreading and cell adhesion. Stimulates the formation and elongation of filopodia. In hippocampal neurons it induces the formation of dendritic filopodia by trafficking the actin-remodeling protein VASP to the tips of filopodia, where it promotes actin elongation. Plays a role in formation of the podosome belt in osteoclasts. Functions as a dominant-negative regulator of isoform 1, suppressing its filopodia-inducing and axon outgrowth-promoting activities. In hippocampal neurons, it increases VASP retention in spine heads to induce spine formation and spine head expansion.

Subunit / interactions. Monomer, when in an inactive conformation in the cytosol. Homodimer in its active, membrane-bound conformation; antiparallel coiled coil-mediated dimer formation. Interacts strongly with CALM3 and weakly with CALM, the CALM3 interaction is essential for function in filopodial extension and motility. Interacts with ECPAS. Interacts with NEO1. Interacts with ITGB1 and ITGB3. Interacts with VASP. Interacts with DCC and ITGB5; the presence of DCC inhibits ITGB5 binding. Interacts with tubulin; ITGB5 or DCC binding inhibits tubulin binding.

Subcellular location. Cytoplasm. Cytosol. Cell projection. Lamellipodium. Ruffle. Cytoskeleton. Filopodium tip. Cell cortex. Filopodium membrane.

Tissue specificity. Ubiquitous.

Post-translational modifications. The initiator methionine for isoform Headless is removed.

Domain organisation. Interaction between the motor domain and the tail leads to an inactive, monomeric conformation. Phospholipid binding via the PH domains leads to the formation of the active, dimeric form of the protein and strongly increases actin-dependent ATPase activity and motor activity. Interacts with membranes containing phosphatidylinositol-3,4,5-trisphosphate via the PH domains. IQ 3 domain mediates high-affinity calcium-dependent binding to CALM3/CLP. The SAH (single alpha-helix) region is characterized by a high content of charged residues which are predicted to stabilize the alpha-helical structure by ionic bonds. It can refold after extension suggesting an in vivo force-dependent function. An anti-parallel coiled coil is located C-terminal to the SAH domain and mediates dimerization.

Miscellaneous. Produced by alternative promoter usage.

Similarity. Belongs to the TRAFAC class myosin-kinesin ATPase superfamily. Myosin family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9HD67-1	1	yes
Q9HD67-2	2
Q9HD67-3	Headless

RefSeq proteins (1): NP_036466* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000048	IQ_motif_EF-hand-BS	Binding_site
IPR000159	RA_dom	Domain
IPR000299	FERM_domain	Domain
IPR000857	MyTH4_dom	Domain
IPR001609	Myosin_head_motor_dom-like	Domain
IPR001849	PH_domain	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR014352	FERM/acyl-CoA-bd_prot_sf	Homologous_superfamily
IPR019748	FERM_central	Domain
IPR019749	Band_41_domain	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR031971	MYO10_CC	Domain
IPR035963	FERM_2	Homologous_superfamily
IPR036124	MYSc_Myo10	Domain
IPR036961	Kinesin_motor_dom_sf	Homologous_superfamily
IPR038185	MyTH4_dom_sf	Homologous_superfamily
IPR040640	MyoX_N_SH3	Domain
IPR041797	MyoX_FERM_C	Domain
IPR051724	Actin_motor_Myosin	Family

Pfam: PF00063, PF00169, PF00373, PF00612, PF00784, PF16735, PF18597, PF21989

UniProt features (148 total): helix 57, strand 38, domain 8, mutagenesis site 7, turn 6, sequence variant 6, region of interest 5, modified residue 5, compositionally biased region 4, binding site 4, splice variant 3, sequence conflict 3, chain 1, coiled-coil region 1

Structure

Experimental structures (PDB)

7 structures.

PDB	Method	Resolution (Å)
5I0H	X-RAY DIFFRACTION	1.8
3AU4	X-RAY DIFFRACTION	1.9
3PZD	X-RAY DIFFRACTION	2.5
3AU5	X-RAY DIFFRACTION	2.55
5I0I	X-RAY DIFFRACTION	3.15
5KG8	ELECTRON MICROSCOPY	9.1
2LW9	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HD67-F1	76.95	0.27

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 104; 113; 160–165; 215

Post-translational modifications (5): 1, 962, 965, 968, 1158

Mutagenesis-validated functional residues (7):

Position	Phenotype
795	abolishes interaction with calm3.
893	abolishes dimerization.
904	abolishes dimerization.
1647	abolishes interaction with tubulin; when associated with d-1650.
1650	abolishes interaction with tubulin; when associated with d-1647.
1718–1719	almost abolishes interaction with dcc.
2002	abolishes interaction with dcc.

Function

Pathways and Gene Ontology

Reactome pathways

15 pathways

ID	Pathway
R-HSA-2029482	Regulation of actin dynamics for phagocytic cup formation
R-HSA-373752	Netrin-1 signaling
R-HSA-9664422	FCGR3A-mediated phagocytosis
R-HSA-1266738	Developmental Biology
R-HSA-1643685	Disease
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System
R-HSA-2029480	Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-422475	Axon guidance
R-HSA-5663205	Infectious disease
R-HSA-9658195	Leishmania infection
R-HSA-9664407	Parasite infection
R-HSA-9664417	Leishmania phagocytosis
R-HSA-9675108	Nervous system development
R-HSA-9824443	Parasitic Infection Pathways

MSigDB gene sets: 368 (showing top): MODULE_52, GCM_MAP4K4, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_REGULATION_OF_CELL_MORPHOGENESIS, PID_NETRIN_PATHWAY, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOCC_RUFFLE, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION, NKX61_01, MODULE_66, GOBP_CELL_CELL_ADHESION, GTGCCTT_MIR506, MODULE_118

GO Biological Process (6): signal transduction (GO:0007165), regulation of cell shape (GO:0008360), positive regulation of cell-cell adhesion (GO:0022409), cytoskeleton-dependent intracellular transport (GO:0030705), regulation of filopodium assembly (GO:0051489), regulation of biological quality (GO:0065008)

GO Molecular Function (13): microfilament motor activity (GO:0000146), calmodulin binding (GO:0005516), ATP binding (GO:0005524), phosphatidylinositol-3,4,5-trisphosphate binding (GO:0005547), spectrin binding (GO:0030507), actin filament binding (GO:0051015), plus-end directed microfilament motor activity (GO:0060002), nucleotide binding (GO:0000166), cytoskeletal motor activity (GO:0003774), actin binding (GO:0003779), protein binding (GO:0005515), cytoskeletal protein binding (GO:0008092), protein-containing complex binding (GO:0044877)

GO Cellular Component (16): ruffle (GO:0001726), nucleolus (GO:0005730), cytosol (GO:0005829), plasma membrane (GO:0005886), cell cortex (GO:0005938), myosin complex (GO:0016459), lamellipodium (GO:0030027), filopodium (GO:0030175), filopodium membrane (GO:0031527), filopodium tip (GO:0032433), neuron projection (GO:0043005), neuronal cell body (GO:0043025), cytoplasm (GO:0005737), cytoskeleton (GO:0005856), membrane (GO:0016020), cell projection (GO:0042995)

Reactome top-level categories

Rollup of top-12 pathways:

Category	Pathways
Fcgamma receptor (FCGR) dependent phagocytosis	1
Axon guidance	1
Leishmania phagocytosis	1
Immune System	1
Innate Immune System	1
Nervous system development	1
Disease	1
Parasitic Infection Pathways	1
Leishmania infection	1
Parasite infection	1
Developmental Biology	1
Infectious disease	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
plasma membrane bounded cell projection	3
protein binding	2
cytoskeletal protein binding	2
protein-containing complex binding	2
binding	2
cell leading edge	2
intracellular membraneless organelle	2
cytoplasm	2
cell periphery	2
filopodium	2
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
regulation of cell morphogenesis	1
regulation of biological quality	1
regulation of cell-cell adhesion	1
positive regulation of cell adhesion	1
cell-cell adhesion	1
intracellular transport	1
filopodium assembly	1
regulation of plasma membrane bounded cell projection assembly	1
biological regulation	1
cytoskeletal motor activity	1
polypeptide conformation or assembly isomerase activity	1
ATP-dependent activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
anion binding	1
phosphatidylinositol phosphate binding	1
actin binding	1
microfilament motor activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
molecular_function	1
nuclear lumen	1
membrane	1
actin cytoskeleton	1

Protein interactions and networks

STRING

1658 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MYO10	VASP	P50552	779
MYO10	CALML3	P27482	746
MYO10	TRAK2	O60296	701
MYO10	TRAK1	Q9UPV9	650
MYO10	TM4SF1	P30408	626
MYO10	PLEK	P08567	599
MYO10	CALM1	P02593	594
MYO10	PLEK2	Q9NYT0	589
MYO10	CALML4	Q96GE6	568
MYO10	CALML6	Q8TD86	567
MYO10	CALML5	Q9NZT1	566
MYO10	CDC42	P21181	564
MYO10	RHOT2	Q8IXI1	547
MYO10	DIAPH3	Q9NSV4	538
MYO10	RMDN2	Q96LZ7	518

IntAct

56 interactions, top by confidence:

A	B	Type	Score
CALML3	MYO10	psi-mi:“MI:0915”(physical association)	0.680
PKN3	ARHGAP10	psi-mi:“MI:0914”(association)	0.680
CALML3	MYO10	psi-mi:“MI:0407”(direct interaction)	0.680
MYO10	CALML3	psi-mi:“MI:0407”(direct interaction)	0.680
DCC	MYO10	psi-mi:“MI:0407”(direct interaction)	0.650
MYO10	DCC	psi-mi:“MI:0915”(physical association)	0.650
CALM1	MYO10	psi-mi:“MI:0407”(direct interaction)	0.560
MYO10	CALM1	psi-mi:“MI:0407”(direct interaction)	0.560
MYO10	Dcc	psi-mi:“MI:0407”(direct interaction)	0.540
MYO10	Dcc	psi-mi:“MI:0915”(physical association)	0.540
MYO10	ITGB5	psi-mi:“MI:0407”(direct interaction)	0.540
PRKCI	NIPSNAP2	psi-mi:“MI:0914”(association)	0.530
JPH4	ZSWIM8	psi-mi:“MI:0914”(association)	0.530
PBXIP1	KCNN4	psi-mi:“MI:0914”(association)	0.530
MYO10	Neo1	psi-mi:“MI:0407”(direct interaction)	0.440
MYO10	TUBA1A	psi-mi:“MI:0407”(direct interaction)	0.440
TUBB2B	MYO10	psi-mi:“MI:0407”(direct interaction)	0.440
MYO10	FSCN1	psi-mi:“MI:0915”(physical association)	0.400
MYO10	HSP90B1	psi-mi:“MI:0915”(physical association)	0.400
MYO10	TRIO	psi-mi:“MI:0915”(physical association)	0.400
ENAH	MYO10	psi-mi:“MI:0915”(physical association)	0.400
ITGB5	DCC	psi-mi:“MI:0915”(physical association)	0.400
PARD6B	PARD3	psi-mi:“MI:0914”(association)	0.350
Actb		psi-mi:“MI:0914”(association)	0.350

BioGRID (164): MYO10 (Affinity Capture-MS), MYO10 (Affinity Capture-MS), MYO10 (Affinity Capture-MS), MYO10 (Affinity Capture-MS), MYO10 (Affinity Capture-MS), MYO10 (Affinity Capture-MS), MYO10 (Affinity Capture-MS), MYO10 (Affinity Capture-MS), MYO10 (Affinity Capture-MS), MYO10 (Affinity Capture-MS), MYO10 (Affinity Capture-MS), MYO10 (Affinity Capture-MS), MYO10 (Affinity Capture-RNA), MYO10 (Affinity Capture-MS), MYO10 (Affinity Capture-RNA)

ESM2 similar proteins: A0MP03, A2AQP0, A5PF48, A7E2Y1, B0I1T2, D3ZJP6, E7F9L8, F1PRN2, F4IUG9, F4JM19, F8VQB6, O00159, O88329, O94832, P08799, P10568, P79114, P91443, P97479, Q01989, Q03479, Q0WPU1, Q13402, Q17LW0, Q17R14, Q1EG27, Q23978, Q23979, Q27966, Q29P71, Q5SUA5, Q5SYD0, Q5ZLA6, Q5ZMC2, Q622K8, Q63355, Q63357, Q6GPA1, Q6PIF6, Q8K3H5

Diamond homologs: A0MP03, A1C4A5, A1DBH2, A2R5J1, A3LYL7, A4RE77, A5DKH0, A5E4A8, A5PF48, A6SED8, A6ZMG6, A6ZZJ1, A7EK16, A7TDZ8, A8N2Y6, A8PWF6, B0CRJ3, B0I1T2, B0Y9Q4, D3ZJP6, E7F9L8, E9Q634, F1PRN2, F4HWY6, F4I460, F4I5Q6, F4IVR7, F4JM19, F8VQB6, O00159, O00160, O43795, O88329, O94832, P05659, P08799, P0CP00, P0CP01, P10568, P10569

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
MYO10	up-regulates	Actin_cytoskeleton_reorganization
MYO10	up-regulates	Axonal_growth_cone_formation
DCC	“up-regulates activity”	MYO10	binding
MYO10	“up-regulates quantity”	DCC	relocalization

Disease & clinical

Clinical variants and AI predictions

ClinVar

430 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	339
Likely benign	13
Benign	16

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
59604	GRCh38/hg38 5p15.2-14.3(chr5:13609772-21930280)x1	Pathogenic
3064964	NM_012334.3(MYO10):c.841_844del (p.Ser281fs)	Likely pathogenic

SpliceAI

6806 predictions. Top by Δscore:

Variant	Effect	Δscore
5:16666790:CCAC:C	acceptor_gain	1.0000
5:16666791:CACC:C	acceptor_gain	1.0000
5:16666793:CCTG:C	acceptor_loss	1.0000
5:16666794:C:A	acceptor_loss	1.0000
5:16666795:T:A	acceptor_loss	1.0000
5:16666799:C:T	acceptor_gain	1.0000
5:16666800:A:T	acceptor_gain	1.0000
5:16668274:TACC:T	donor_loss	1.0000
5:16668275:A:AC	donor_gain	1.0000
5:16668276:C:CA	donor_loss	1.0000
5:16668276:C:CC	donor_gain	1.0000
5:16668276:CCT:C	donor_gain	1.0000
5:16668276:CCTCA:C	donor_gain	1.0000
5:16668465:TGCA:T	acceptor_gain	1.0000
5:16668466:GCA:G	acceptor_gain	1.0000
5:16668467:CA:C	acceptor_gain	1.0000
5:16668467:CAC:C	acceptor_gain	1.0000
5:16668469:C:CC	acceptor_gain	1.0000
5:16668477:C:CT	acceptor_gain	1.0000
5:16668478:A:T	acceptor_gain	1.0000
5:16670083:A:AC	donor_gain	1.0000
5:16670084:C:CC	donor_gain	1.0000
5:16670520:TCTCA:T	donor_loss	1.0000
5:16670521:CTCA:C	donor_loss	1.0000
5:16670522:TCACC:T	donor_loss	1.0000
5:16670523:CACCT:C	donor_loss	1.0000
5:16670524:A:T	donor_loss	1.0000
5:16670665:T:TA	donor_gain	1.0000
5:16671538:CCAGC:C	acceptor_gain	1.0000
5:16671539:CAGC:C	acceptor_gain	1.0000

AlphaMissense

13681 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:16672812:A:G	L1729P	1.000
5:16679963:A:G	L1509P	1.000
5:16680027:A:G	W1488R	1.000
5:16680027:A:T	W1488R	1.000
5:16681937:A:G	W1375R	1.000
5:16681937:A:T	W1375R	1.000
5:16694585:A:G	W1196R	1.000
5:16694585:A:T	W1196R	1.000
5:16668290:A:G	F2021S	0.999
5:16668324:A:C	Y2010D	0.999
5:16668346:A:C	F2002L	0.999
5:16668346:A:T	F2002L	0.999
5:16668348:A:G	F2002L	0.999
5:16668407:A:T	V1982D	0.999
5:16668413:A:T	V1980D	0.999
5:16668428:A:T	V1975D	0.999
5:16668434:A:G	L1973S	0.999
5:16668438:A:G	W1972R	0.999
5:16668438:A:T	W1972R	0.999
5:16668440:A:G	L1971P	0.999
5:16670561:A:G	W1950R	0.999
5:16670561:A:T	W1950R	0.999
5:16672772:A:C	F1742L	0.999
5:16672772:A:T	F1742L	0.999
5:16672773:A:G	F1742S	0.999
5:16672774:A:G	F1742L	0.999
5:16672800:A:G	L1733P	0.999
5:16673743:A:T	V1704D	0.999
5:16674871:A:G	L1649P	0.999
5:16674981:T:A	K1612N	0.999

dbSNP variants (sampled 300 via entrez): RS1000001476 (5:16811725 A>G), RS1000004365 (5:16746437 G>A), RS1000009127 (5:16718962 T>G), RS1000011631 (5:16783192 G>A), RS1000033035 (5:16788710 A>T), RS1000042407 (5:16700936 A>C), RS1000043156 (5:16856801 A>G), RS1000044593 (5:16797042 T>C), RS1000058406 (5:16917350 T>C), RS1000071330 (5:16924019 G>A), RS1000072892 (5:16702581 C>T), RS1000073431 (5:16922508 A>G), RS1000081523 (5:16732829 T>C), RS1000095955 (5:16893372 G>A), RS1000109742 (5:16673248 G>C)

Disease associations

OMIM: gene MIM:601481 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST001762_881	Obesity-related traits	2.000000e-06
GCST001850_27	Major depressive disorder	2.000000e-08
GCST001859_18	Thiazide-induced adverse metabolic effects in hypertensive patients	4.000000e-06
GCST004102_5	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease	9.000000e-06
GCST005868_6	Circulating odd-numbered chain saturated fatty acid levels (C17:0)	1.000000e-08
GCST007061_6	Response to antidepressants (symptom remission)	3.000000e-06
GCST007450_1	Normal facial asymmetry (deformation magnitude)	2.000000e-06
GCST009391_1667	Metabolite levels	5.000000e-06
GCST009391_791	Metabolite levels	2.000000e-06
GCST90044902_2	Polycystic ovary syndrome (adjusted for age)	2.000000e-08
GCST90044903_2	Polycystic ovary syndrome (adjusted for age and BMI)	3.000000e-06

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0005118	IGFBP-1 measurement
EFO:0005937	longitudinal BMI measurement
EFO:0009751	facial asymmetry measurement
EFO:0010470	carnosine measurement
EFO:0010395	sphingomyelin 22:0 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

79 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, increases expression, affects expression	7
Aflatoxin B1	affects methylation, decreases expression, decreases methylation, increases expression	5
Benzo(a)pyrene	affects methylation, decreases expression, increases expression	4
trichostatin A	affects cotreatment, increases expression, decreases expression	3
sodium arsenite	affects methylation, increases expression	3
Estradiol	affects cotreatment, increases expression, affects expression	3
Cadmium Chloride	increases expression	3
bisphenol A	decreases expression, affects cotreatment, increases expression	2
mercuric bromide	increases expression, affects cotreatment	2
Cisplatin	affects cotreatment, decreases expression, decreases response to substance, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
FR900359	affects phosphorylation	1
sotorasib	affects cotreatment, decreases expression	1
bufotalin	decreases expression	1
methylmercuric chloride	increases expression	1
lasiocarpine	increases expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
glycidyl methacrylate	increases expression	1
methylselenic acid	decreases expression	1
salinomycin	decreases expression	1
methoxyacetic acid	increases reaction, increases expression	1
3,4-dichloroaniline	increases expression	1
beta-lapachone	decreases expression, increases expression	1
arsenite	affects binding, decreases reaction	1
cobaltous chloride	decreases expression	1
9,10-dihydro-9,10-dihydroxybenzo(a)pyrene	decreases expression	1
manganese chloride	decreases expression, increases abundance	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
aflatoxin B2	increases methylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.